2022
SHINE CEO to Deliver Keynote at Wisconsin Entrepreneurs’ Conference
CEO and founder Greg Piefer will give an invited presentation at the Wisconsin Entrepreneurs’ Conference in Milwaukee. On Thursday, June 2 at 8:45 a.m., Piefer will present the opening keynote before engaging in discussion with the audience.
SHINE Announces Chris Vessell as General Manager of Therapeutics Division
JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.
SHINE and U.S. Department of Homeland Security Expand Contraband Detection
SHINE announced it has been awarded a potential 42-month contract with a total funding potential of approximately $16.8 million to help the U.S. Department of Homeland Security (DHS)
SHINE Appoints Financial and Energy Industry Veterans to Board of Directors
SHINE, a next-generation nuclear technology company, today announced the appointments of global technology, energy sector and business veterans Holli C. Ladhani and Janet S. Wong to the company’s board of directors.
SHINE Founder, CEO Attending White House Summit on Fusion Energy
Tomorrow, March 17, 2022 Tune in via livestream as Greg Piefer joins other industry experts to help shape vision for commercial fusion energy Today, the Biden-Harris Administration released additional information on its plans to develop [...]
SHINE Technologies and ImaginAb Announce Lutetium-177 Clinical Supply Agreement
SHINE to supply n.c.a. Lu-177 for the clinical development of ImaginAb investigational radiopharmaceuticals
SHINE and Telix Pharmaceuticals Announce Lutetium-177 Clinical Supply Agreement
SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.
SHINE Europe B.V. Designing Advanced Medical Isotopes Facility in the Netherlands
A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.
SHINE and Department of Energy Sign First-ever Contracts Under Uranium Lease and Take-back Program for Molybdenum-99
Vital medical radioisotope used in over 40,000 medical diagnostic procedures in the United States every day SHINE’s Mo-99 production facility steadily progressing construction in Janesville, Wis.Credit: SHINE Technologies LLC JANESVILLE, Wis., Jan. 6 [...]
2021
SHINE’s new name highlights technology competencies and multiple phase opportunities
A test engineer works in SHINE's manufacturing facility in Fitchburg, Wis. JANESVILLE, Wis., Sept. 21, 2021 – SHINE Medical Technologies LLC today announced that the company has changed its name to SHINE [...]
SHINE commemorates completion of new corporate headquarters
SHINE Medical Technologies LLC today announced the completion of its new corporate headquarters. The company now has three facilities on its campus on U.S. Highway 51 across from the Southern Wisconsin Regional Airport.
SHINE Medical Technologies Closes $150-million Series C-5 Financing
SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing. Koch Disruptive Technologies (KDT) led the round, which also included participation by Fidelity Management & Research Company, Baillie Gifford and other new and current investors.
SHINE Medical announces agreement with MURR
SHINE Medical Technologies LLC today announced that it has entered a multi-year contract with the University of Missouri Research Reactor, or MURR®, for irradiation of ytterbium-176.
SHINE, EDH enter distribution agreement for SHINE’s non-carrier-added Lu-177
SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries
SHINE selects Netherlands for European isotope production facility
SHINE Medical Technologies LLC today announced that it has selected the municipality of Veendam in the province of Groningen, the Netherlands, as the location of its European medical isotope production facility. The decision is the culmination of a year-long search process that included the review of more than 50 proposals from sites across Europe.
SHINE, Phoenix merger focused on advancing fusion technology
JANESVILLE and FITCHBURG, Wis., April 20, 2021 – SHINE Medical Technologies LLC and Phoenix LLC today announced that the companies have completed a merger under which Phoenix has become a wholly owned subsidiary of SHINE.
SHINE appoints ESG, marketing experts to board.
JANESVILLE, Wis., March 18, 2021 – SHINE Medical Technologies LLC today announced the appointments of Jean Rogers, Ph.D., an environmental, social and governance (ESG) expert, and Tamanna Bembenek, Ph.D., a global marketing leader, to the company’s board of directors. Dr. Rogers brings to SHINE’s board more than two decades of experience advising companies on environmental, social and governance (ESG) criteria, and long-term value creation. She is the founder and former chief executive officer of the Sustainability Accounting Standards Board, or SASB.
SHINE announces weathertight production facility
SHINE Technologies announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building has been certified as weathertight, a major milestone with significance for SHINE.
2020
SHINE breaks ground on HQ and Therapeutics production facility
SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000-square-foot facility that will house its corporate headquarters and a large-scale production facility for the Therapeutics division it established last year.
Von Gahlen building supercell for SHINE
SHINE Medical Technologies LLC and Von Gahlen International Inc. today announced that Von Gahlen will build and install the “supercell,” a bank of 10 hot cells, for SHINE’s U.S. medical isotope production facility in Janesville, Wis.
SHINE announces first sales of n.c.a. Lu-177
SHINE announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lutetium-177, or Lu-177, is a therapeutic isotope in demand by clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.
SHINE Receives Diversity Award
SHINE Medical Technologies today announced that it has been named the recipient of the sixth annual YWCA Rock County Dorothy Height Diversity in the Workplace Award. SHINE was presented the award at the YWCA Rock County Racial Justice Conference on Nov. 12, 2020.
SHINE closes $80-million
SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced today that it has closed an $80-million Series C financing. Fidelity Management and Research Company LLC was the largest investor in the round, which also included participation from other new investors and the company’s current investors.
NRC issues review schedule for SHINE application
SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) expects to make a final determination regarding the issuance of an operating license to SHINE by October 2021. SHINE’s application for a license to operate the medical isotope production facility that it is building in Janesville, Wis., was accepted and docketed by the NRC last October.
SHINE & IOCB deliver Lu-177 doses to GE
SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).